Maze Therapeutics, Inc.
MAZENasdaqCIK 1842295HealthcareFiscal year ends Dec 31
Reports and events: 28 filings
Newest first, by EDGAR acceptance time (Eastern). Each filing’s page lists its documents on sec.gov and, for 10-K and 10-Q reports, the extracted sections.
What the forms are: 10-K, 10-Q, 8-K, Form 4, DEF 14A, Schedule 13D, Schedule 13G, amendments, accession numbers.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2026-10-1616:05 ET | 8-K | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001193125-26-424067 |
| 2026-08-1716:16 ET | 8-K | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-354092 |
| 2026-08-1116:48 ET | 10-Q | Quarterly reportPeriod 2026-06-30 | 0001193125-26-344903 |
| 2026-08-1116:45 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-344878 |
| 2026-06-1016:15 ET | 8-K | 5.07 Shareholder vote results | 0001193125-26-265858 |
| 2026-05-2217:24 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001193125-26-237199 |
| 2026-05-1216:11 ET | 10-Q | Quarterly reportPeriod 2026-03-31 | 0001193125-26-219430 |
| 2026-05-1216:07 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-219398 |
| 2026-04-2816:30 ET | DEF 14A | Proxy statementPeriod 2026-06-08 | 0001140361-26-017463 |
| 2026-04-2216:56 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-170701 |
| 2026-03-2507:11 ET | 10-K | Annual reportPeriod 2025-12-31 | 0001193125-26-122778 |
| 2026-03-2507:08 ET | 8-K | 2.02 Results of operations; 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-122774 |
| 2026-02-0416:45 ET | 8-K | 1.01 Entry into a material agreement; 1.02 Termination of a material agreement; 2.03 New direct financial obligation | 0001193125-26-037747 |
| 2025-11-0616:27 ET | 10-Q | Quarterly reportPeriod 2025-09-30 | 0001193125-25-269689 |
| 2025-11-0616:21 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-25-269624 |
| 2025-10-1716:15 ET | S-1 | Registration statement | 0001193125-25-242526 |
| 2025-10-0607:30 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001193125-25-230926 |
| 2025-09-1107:48 ET | 8-K | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-25-200760 |
| 2025-09-0207:00 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001193125-25-193353 |
| 2025-08-1216:08 ET | 10-Q | Quarterly reportPeriod 2025-06-30 | 0000950170-25-107306 |
| 2025-08-1216:06 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-25-107299 |
| 2025-05-1416:06 ET | 10-Q | Quarterly reportPeriod 2025-03-31 | 0000950170-25-071375 |
| 2025-05-1416:04 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-25-071357 |
| 2025-03-3107:34 ET | 10-K | Annual reportPeriod 2024-12-31 | 0000950170-25-047208 |
| 2025-03-3107:32 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-25-047207 |
| 2025-01-3006:57 ET | S-1/A | Registration statement, amended | 0001193125-25-016039 |
| 2025-01-2706:07 ET | S-1/A | Registration statement, amended | 0001193125-25-012638 |
| 2025-01-0716:16 ET | S-1 | Registration statement | 0001193125-25-002851 |
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 29, 2026, 16:22 ET. Listed shows no prices and gives no investment advice.